Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Coivas vs NuBloom

Coivas
Graded #198

Lower grade

vs+2.799999999999997
NuBloom
Graded #139

Higher grade

The verdict

NuBloom takes it — 69/100 to 66.2/100.

NuBloom grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. NuBloom is a women's metabolic-health telehealth practice founded by family and integrative-medicine physician Dr.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueNuBloom +2
70
72
Dose & formulationCoivas +10
64
54
Clinical oversightCoivas +2
84
82
Labs & monitoringNuBloom +7
54
61
FulfillmentNuBloom +7
78
85
Contract termsNuBloom +35
20
55
Coivas · left barNuBloom · right bar

The numbers

MetricCoivasNuBloom
WeighScore66.2/10069/100
GradeCC
Scorecard rank#198#139
Semaglutide$149/mo (quarterly plan, compounded)$149/mo (2.4 mg dose, compounded)
Tirzepatide$229/mo (quarterly plan, compounded)$279/mo (15 mg dose, compounded)
CoverageCoverage not published49 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Coivas

Graded #198 · C

Strengths

  • All-inclusive pricing: one price covers doctor consult, prescription, shipping and support
  • Compounded semaglutide from $149/mo and tirzepatide from $229/mo on the quarterly plan
  • Names its clinical provider (Arora Health & Aesthetics, LLC) and cites USP 797 / NABP-accredited pharmacies
  • Available in all 50 states; 24/7 support; HSA/FSA eligible; money-back guarantee
  • Most patients approved in under 2 hours; refund if no provider visit or prescription occurs

Where it loses points

  • Dispensing pharmacies described only by category (503A/503B, NABP-accredited) - not named individually
  • Lower quarterly headline price requires a 3-month commitment; monthly plan costs more ($179/$289)
  • Money-back guarantee has strict adherence/verification conditions and no partial/prorated refunds
  • No brand-name Wegovy/Zepbound/Mounjaro/Ozempic - compounded injectable only; binding NY arbitration
NuBloom

Graded #139 · C

Strengths

  • Transparent, openly published pricing: compounded semaglutide $149/mo and tirzepatide $279/mo as flexible month-to-month subscriptions
  • Founded and medically led by a named physician (Dr. Marianne Pinkston Mueller, family/integrative medicine, 25+ years)
  • Whole-person model pairs GLP-1s with hormone, gut-health and longevity care plus in-depth lab testing
  • State coverage published openly: 49 states listed on the site (all except Mississippi)
  • Optional 90-day 1:1 coaching program with weekly meetings and unlimited text support ($599/mo)

Where it loses points

  • Compounding pharmacy partners are not named anywhere on the site — a transparency gap
  • NuBloom's own LegitScript/PCAB status is not displayed; only its telehealth partner is certified
  • Compounded medications are not FDA-approved; one FAQ loosely calls them 'FDA-approved,' contradicting the product pages
  • All sales are final and medical consult fees are non-refundable; no returns on prescription products
  • Disputes go to binding individual arbitration; the Terms' governing-law state is left as an unfilled '[STATE]' placeholder

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard